NASDAQ:HTGM HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Free HTGM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$5.01▼$6.8052-Week Range N/AVolume773,040 shsAverage Volume294,806 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock Analysis Get HTG Molecular Diagnostics alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About HTG Molecular Diagnostics Stock (NASDAQ:HTGM)HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. HTGM Stock News HeadlinesJanuary 4, 2024 | morningstar.comHTG Molecular Diagnostics Inc HTGMQSeptember 26, 2023 | uk.investing.comHTG Molecular Diagnostics Inc (HTGMQ)March 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.August 26, 2023 | benzinga.comMolecular Diagnostics Market Research Report 2023 Growth, Recent Trends and Forecast to 2028 by Key PlayersJune 6, 2023 | msn.comHTG Molecular stock tanks in wake of Chapter 11 bankruptcy filingJune 6, 2023 | finance.yahoo.comWhy Are HTG Molecular Diagnostics Shares Plunging TodayJune 6, 2023 | investorplace.comWhy Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?May 18, 2023 | finance.yahoo.comHTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International ConventionMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.May 16, 2023 | finance.yahoo.comHTG Highlights the Advantages of Its Drug Discovery EngineMay 11, 2023 | finanznachrichten.deHTG Molecular Diagnostics, Inc.: HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business HighlightsMay 10, 2023 | finance.yahoo.comHTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business HighlightsApril 25, 2023 | finance.yahoo.comHTG Provides Update on Drug Discovery Partnering InitiativeApril 19, 2023 | msn.comHC Wainwright & Co. Reiterates HTG Molecular Diagnostics (HTGM) Buy RecommendationApril 18, 2023 | finance.yahoo.comHTG Announces Key First Quarter Milestone Achievements for Drug DiscoveryApril 6, 2023 | finance.yahoo.comHTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19April 2, 2023 | finance.yahoo.comHTG Molecular Diagnostics Full Year 2022 Earnings: EPS Misses ExpectationsMarch 24, 2023 | msn.comWhy Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketJanuary 25, 2023 | seekingalpha.comHTGM HTG Molecular Diagnostics, Inc.January 9, 2023 | finance.yahoo.comHTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access EventJanuary 6, 2023 | msn.comHTG Molecular Diagnostics expects FY22 revenue above consensusJanuary 6, 2023 | ca.finance.yahoo.comHTG Announces Certain Preliminary 2022 Unaudited Financial ResultsJanuary 6, 2023 | finance.yahoo.comHTG Announces Certain Preliminary 2022 Unaudited Financial ResultsDecember 30, 2022 | bizjournals.comHTG Molecular Diagnostics of Tucson raises $10M in public offeringDecember 29, 2022 | msn.comPeering Into HTG Molecular Diagnostics's Recent Short InterestDecember 28, 2022 | finance.yahoo.comHTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast SeriesDecember 27, 2022 | msn.comWhat Does HTG Molecular Diagnostics' Debt Look Like?See More Headlines Receive HTGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:HTGM CUSIPN/A CIK1169987 Webwww.htgmolecular.com Phone(520) 547-2827Fax520-547-2837Employees84Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,590,000.00 Net Margins-324.25% Pretax Margin-324.05% Return on Equity45.52% Return on Assets8.93% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio1.30 Sales & Book Value Annual Sales$6.37 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.44 per share Price / BookN/AMiscellaneous Outstanding Shares2,210,000Free Float2,156,000Market CapN/A OptionableOptionable Beta0.99 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesJohn L. LubniewskiPresident, Chief Executive Officer & DirectorShaun D. McMeansCFO, Secretary, Treasurer & SVP-AdministrationByron T. LawsonChief Commercial Officer & Senior Vice PresidentLaura L. GodlewskiChief Accounting Officer & Vice President-FinanceSam M. RuaSenior VP-Regulatory Affairs & Quality SystemsKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All CompetitorsInsidersStephen BaratSold 888 sharesTotal: $710.40 ($0.80/share) HTGM Stock Analysis - Frequently Asked Questions Should I buy or sell HTG Molecular Diagnostics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HTGM shares. View HTGM analyst ratings or view top-rated stocks. What is HTG Molecular Diagnostics' stock price target for 2024? 1 Wall Street analysts have issued 1-year price objectives for HTG Molecular Diagnostics' stock. Their HTGM share price targets range from $6.00 to $6.00. On average, they anticipate the company's share price to reach $6.00 in the next year. View analysts price targets for HTGM or view top-rated stocks among Wall Street analysts. How were HTG Molecular Diagnostics' earnings last quarter? HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its quarterly earnings data on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.60). The medical research company earned $2.52 million during the quarter, compared to analysts' expectations of $2.90 million. HTG Molecular Diagnostics had a negative net margin of 324.25% and a positive trailing twelve-month return on equity of 45.52%. During the same period in the previous year, the firm earned ($1.05) earnings per share. What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO? 11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of HTG Molecular Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did HTG Molecular Diagnostics IPO? HTG Molecular Diagnostics (HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers. This page (NASDAQ:HTGM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HTG Molecular Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.